Know Cancer

forgot password

Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy

21 Years
75 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy

Non-invasive measurements of breast tissue optical properties will be performed on the skin
surface using a specially designed PMS measurement probe which is similar in shape to an
ultrasound probe. The PMS probe is embedded with optic fibers set at a fixed separation. The
FDPM probe will be placed on different areas of the breast including areas suspected to have
disease and areas appearing to be normal. The diseased location will be identified by
clinical palpation. Some mild tissue compression will be performed within comfort tolerance
of the patient during the application of the PMS probe.

When the probe is in position, the laser will be activated and a measurement will be taken.
Each measurement will require about 30-60 seconds to record the data and calculate optical
properties. The probe will then be turned off and moved to a new position for further
measurements. The process will be repeated until an adequate number of measurements are
performed (about 10-20). The whole process should take about 30 to 90 minutes.

Anticipate Risk and Benefit:

The optical scan is not expected to cause any pain, burning, or discomfort during or after
the exam. There may be risks, however, that are currently unforeseeable. During all
measurements, the laser will be turned on only when needed. Although not required for
safety, subjects may wear protective eye goggles if requested.

There is no therapeutic benefit to the subject, especially none that might influence the
indication for the diagnostic procedure as indicated. However, information obtained may lead
to a new form of non-invasive imaging for the early detection of breast cancer.

Inclusion Criteria:

- Female non-pregnant and age greater than or equal to 21 years old but less than 75
years old

- Diagnosed with breast cancer and will be receiving neoadjuvant chemotherapy

Exclusion Criteria:

- Female pregnant and age less than 21 years old and have no diagnosis of breast cancer

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Principal Investigator

David Hsiang, M.D

Investigator Role:

Principal Investigator

Investigator Affiliation:

Beckman Laser Institute University of California Irvine


United States: Institutional Review Board

Study ID:

NTROI CA-105480-05



Start Date:

June 2002

Completion Date:

January 2011

Related Keywords:

  • Breast Cancer
  • Breast cancer receiving chemotherapy
  • Breast Neoplasms



Chao Family Comprehensive Cancer CenterOrange, California  92868
Beckman Laser Institute University of California IrvineIrvine, California  92612